(Reuters) – Pfizer Inc said on Friday it signed a multi-year agreement with Gilead Sciences Inc to manufacture and supply the company’s antiviral drug remdesivir for COVID-19 patients.
The U.S. drugmaker would provide contract manufacturing services at its facility in Kansas to produce the drug.
(Reporting by Manas Mishra in Bengaluru; Editing by Anil D’Silva)
